echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Biochemistry News > Biotechnology News > Johnson & Johnson BCMA/CD3 dual antibody application for clinical application

    Johnson & Johnson BCMA/CD3 dual antibody application for clinical application

    • Last Update: 2021-04-19
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On April 1, the CDE official website showed that the clinical trial application of Johnson & Johnson's BCMA/CD3 bispecific antibody Teclistamab injection (acceptance number: JXSL2101002/3) was accepted by the CDE.


    Teclistamab is a bispecific antibody developed using Genmab DuoBody® technology that can simultaneously target T cell CD3 and multiple myeloma (MM) cell BCMA.


    In December 2020, Johnson & Johnson announced the data of the first human phase I clinical study of teclistamab (NCT03145181), which evaluated the efficacy of teclistamab in the treatment of patients with relapsed or refractory multiple myeloma (MM).


    research shows.


    Domestic companies that have deployed BCMA/CD3 bispecific antibody therapy include Amgen (AMG 701) and Shandong New Era.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.